Riskpilot← Back to searchSign inGet full accessUltimovacs AB
ABIn liquidationOrg 5591443162Dag Hammarskjölds Väg 58 CResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 9,5M
-21% vs 2023
EBITDA margin
-20.8%
-2% vs 2023
Equity ratio
64.9%
Financial strength
Net profit 2024
SEK -1,9M
-3% vs 2023
| Revenue | SEK 9,5M | -21% |
| EBITDA | SEK -2M | -2% |
| Net profit | SEK -1,9M | -3% |
| Total assets | SEK 2,5M | -34% |
| Equity | SEK 1,6M | +1% |
| Employees | 0 | — |
Legal name
Ultimovacs AB
Org number
5591443162
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 januari 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva forskning och utveckling inom biomedicin, medicin, immunologi och cancer samt därmed förenlig verksamhet.
Address
Dag Hammarskjölds Väg 58 C
Email
anna.romell.stenmark@lindahl.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10 250 | 12 000 | 9 524 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −5 736 | −12 277 | −4 242 | −1 946 | −1 985 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −5 736 | −12 277 | −4 242 | −1 946 | −1 985 |
| Net financials | −6 | −5 | 4 | 66 | 50 |
| Profit before tax | −5 742 | −12 282 | −4 239 | −1 880 | −1 934 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −5 742 | −12 282 | −4 239 | −1 880 | −1 934 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 494 | 1 379 | 5 912 | 3 755 | 2 488 |
| Equity | −58 | −616 | 3 483 | 1 603 | 1 615 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 553 | 1 995 | 2 429 | 2 152 | 872 |
| Total debt | 553 | 1 995 | 2 429 | 2 152 | 872 |
EBITDA margin
-20.8%
This company
15.8%
Market median
-232% vs market
20202024
Equity ratio
64.9%
This company
38.2%
Market median
+70% vs market
20202024
Return on equity
-119.8%
This company
18.4%
Market median
-751% vs market
20202024
Net profit margin
-20.3%
This company
8.1%
Market median
-351% vs market
20202024
Asset turnover
3.83×
This company
1.12×
Market median
+242% vs market
20202024
Debt / equity
0.54×
This company
0.62×
Market median
+13% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AB Liquidator | Liquidator | 2025 |
| Former (4) | ||
YG Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
SM Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2024 |
IM Chief Auditor | Chief Auditor | 2024 – 2026 |
ON Authorized Recipient of Service | Authorized Recipient of Service | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (8) | ||
| Chairman | 2025 – 2025 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2025 – 2025 | |
| Deputy Board Member | 2025 – 2025 | |
| Board of Directors | 2020 – 2024 | |
| Chairman | 2020 – 2025 | |
| Deputy Board Member | 2025 – 2025 | |
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ZELLUNA ASA
Ultimovacs AB (this company)Board members of Ultimovacs AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ylva Gunilla Ekström | Chief Executive Officer | 0 companies |
| Anna Birgitta Romell Stenmark | Liquidator | 0 companies |
| Sara Maria Mangsbo | Authorized Recipient of Service | 0 companies |
| Ida Maria Brandt | Chief Auditor | 0 companies |
| Orla Noreen Mc Callion | Authorized Recipient of Service | 0 companies |
| Hans Vassgård Eid | Chairman | 0 companies |
| Jens Egil Torbjørn Bjørheim | Board of Directors | 0 companies |
| Anders Holm | Board of Directors | 0 companies |
| Namir Jafar Hassan | Deputy Board Member | 0 companies |
| Ingunn Hagen Westgaard | Board of Directors | 0 companies |
| Carlos David Freitas De Sousa | Chairman | 0 companies |
| Joachim Ask Midttun | Deputy Board Member | 0 companies |
| Øyvind Kongstun Arnesen | Chairman | 0 companies |